Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

TCR for identifying PRAME antigen

A variable, β-chain technology, applied in the field of TCR, can solve problems such as normal cell damage

Active Publication Date: 2017-03-22
XLIFESC LTD
View PDF3 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For the treatment of the above diseases, methods such as chemotherapy and radiotherapy can be used, but all of them will cause damage to their own normal cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • TCR for identifying PRAME antigen
  • TCR for identifying PRAME antigen
  • TCR for identifying PRAME antigen

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0142] Example 1 Cloning of PRAME Antigen Short Peptide-Specific T Cells

[0143] Peripheral blood lymphocytes (PBL) from healthy volunteers with genotype HLA-A0201 were stimulated with a synthetic short peptide GLSNLTHVL (SEQ ID NO.:9; Beijing Saibaisheng Gene Technology Co., Ltd.). The GLSNLTHVL short peptide was refolded with biotin-labeled HLA-A0201 to prepare pHLA haploids. These haploids were combined with PE-labeled streptavidin (BD Company) to form PE-labeled tetramers, and the tetramers and anti-CD8-APC double-positive cells were sorted. Sorted cells were expanded and subjected to secondary sorting as described above, followed by monoclonalization by limiting dilution. Monoclonal cells were stained with tetramers, and the double-positive clones screened were as follows: image 3 shown.

Embodiment 2

[0144] Example 2 Obtaining the construction of TCR gene and carrier of PRAME antigen short peptide-specific T cell clone

[0145] with Quick-RNA TM MiniPrep (ZYMO research) extracted the total RNA of the HLA-A0201-restricted T cell clones screened in Example 1 for the short antigenic peptide GLSNLTHVL-specific and HLA-A0201 restricted. The cDNA was synthesized using clontech's SMART RACE cDNA amplification kit, and the primers used were designed at the C-terminal conserved region of the human TCR gene. The sequence was cloned into T vector (TAKARA) for sequencing. It should be noted that this sequence is complementary and does not contain introns. After sequencing, the sequence structures of the TCR α chain and β chain expressed by the double-positive clone are shown in Figure 1 and Figure 2, respectively. Figure 1a , Figure 1b , Figure 1c , Figure 1d , Figure 1e with Figure 1f They are the amino acid sequence of TCRα chain variable domain, the nucleotide sequence...

Embodiment 3

[0155] Example 3 Expression, refolding and purification of PRAME antigen short peptide-specific soluble TCR

[0156] In order to obtain a soluble TCR molecule, the α and β chains of the TCR molecule of the present invention may only include their variable domains and part of the constant domains respectively, and a cysteine ​​residue is introduced into the constant domains of the α and β chains respectively To form an artificial interchain disulfide bond, the positions of the introduced cysteine ​​residues are Thr48 of TRAC*01 exon 1 and Ser57 of TRBC2*01 exon 1; the amino acid sequence and nucleotides of the α chain sequence as Figure 4a with Figure 4b As shown, the amino acid sequence and nucleotide sequence of its β chain are as follows Figure 5a with Figure 5b The introduced cysteine ​​residues are shown in bold and underlined letters. The target gene sequences of the above TCRα and β chains were synthesized and inserted into the expression vector pET28a+ (Novagene...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a T cell receptor (TCR) capable of specifically binding with a short peptide GLSNLTHVL derived from a PRAME antigen. The short peptide GLSNLTHVL can form a compound with HLA A0201 and is presented on the cell surface together with the HLA A0201. The invention further provides a nucleic acid molecule encoding the TCR and a carrier including the nucleic acid molecule. In addition, the invention further provides a cell transducing the TCR.

Description

technical field [0001] The present invention relates to TCRs capable of recognizing short peptides derived from PRAME antigens. The present invention also relates to PRAME-specific T cells obtained by transducing the above TCRs, and their use in the prevention and treatment of PRAME-related diseases. Background technique [0002] PRAME is a preferentially expressed antigen of melanoma (PRAME), which is expressed in 88% of primary and 95% of metastatic melanoma (Ikeda H, etal. Immunity, 1997, 6(2): 199-208) , normal skin tissue and benign melanocytes are not expressed. After PRAME is produced in cells, it is degraded into small molecular polypeptides, and combines with MHC (major histocompatibility complex) molecules to form a complex, which is presented to the cell surface. GLSNLTHVL is a short peptide derived from the PRAME antigen and is a target for the treatment of PRAME-associated diseases. In addition to melanoma, PRAME is also expressed in a variety of tumors, inclu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/725C12N15/12C12N15/867C12N5/10A61K38/17A61P35/00A61P37/02
CPCA61K38/00C07K14/7051C07K2319/00
Inventor 李懿相瑞瑞吴万里林燕梅李思韵
Owner XLIFESC LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products